Literature DB >> 11927115

Bleeding patterns and clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up to two years.

Margarete Hidalgo1, Luis Bahamondes, Marcos Perrotti, Juan Diaz, Cecilia Dantas-Monteiro, Carlos Petta.   

Abstract

The objectives of this study were to evaluate the bleeding patterns and clinical performance during the first 2 years of use of an intrauterine system releasing 20 microg/day of levonorgestrel (LNG-IUS, Mirena). Two-hundred-fifty-six women accepted use of Mirena from April 1998 through September 1998. The gross cumulative discontinuation rate due to pregnancy and expulsion were significantly higher in women who used the device because of heavy bleeding. There was one pregnancy at the 15th month of use after an inadvertent expulsion of the device. The continuation rate was 66.2 at the end of the second year. Forty-four percent of women reported amenorrhea at the 6th month of use. This rate maintained stability at 50% after 12 and 24 months of use. Spotting was present in 25% of the users at 6 months, decreasing to 8% and 11% at 18 and 24 months, respectively. Oligomenorrhea was described by one-quarter of women and was similar at each observation period. Removals due to menstrual bleeding problems were concentrated in the first 6 months of use and mostly due to amenorrhea or menorrhagia. In conclusion, LNG-IUS showed a high contraceptive efficacy and a good continuation rate up to 2 years. In addition, a reduction of blood loss was observed a few months after insertion.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11927115     DOI: 10.1016/s0010-7824(01)00302-x

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  24 in total

1.  Tamoxifen for the prevention of unscheduled bleeding in new users of the levonorgestrel 52-mg intrauterine system: a randomized controlled trial.

Authors:  Megan A Cohen; Katharine B Simmons; Alison B Edelman; Jeffrey T Jensen
Journal:  Contraception       Date:  2019-06-18       Impact factor: 3.375

2.  Randomized placebo-controlled trial of CDB-2914 in new users of a levonorgestrel-releasing intrauterine system shows only short-lived amelioration of unscheduled bleeding.

Authors:  P Warner; A Guttinger; A F Glasier; R J Lee; S Nickerson; R M Brenner; H O D Critchley
Journal:  Hum Reprod       Date:  2009-11-07       Impact factor: 6.918

3.  Immediate post-abortion insertion of intrauterine contraceptives (IUC) in a diverse urban population.

Authors:  DeShawn Taylor; Shannon Connolly; Sue Ann Ingles; Carey Watson; Penina Segall-Gutierrez
Journal:  J Immigr Minor Health       Date:  2014-06

4.  Naproxen or estradiol for bleeding and spotting with the levonorgestrel intrauterine system: a randomized controlled trial.

Authors:  Tessa Madden; Sarah Proehl; Jenifer E Allsworth; Gina M Secura; Jeffrey F Peipert
Journal:  Am J Obstet Gynecol       Date:  2011-09-24       Impact factor: 8.661

Review 5.  Efficacy and safety of long-acting reversible contraception.

Authors:  Amy Stoddard; Colleen McNicholas; Jeffrey F Peipert
Journal:  Drugs       Date:  2011-05-28       Impact factor: 9.546

6.  Association of short-term bleeding and cramping patterns with long-acting reversible contraceptive method satisfaction.

Authors:  Justin T Diedrich; Sanyukta Desai; Qiuhong Zhao; Gina Secura; Tessa Madden; Jeffrey F Peipert
Journal:  Am J Obstet Gynecol       Date:  2014-07-18       Impact factor: 8.661

7.  Benefit-risk assessment of the levonorgestrel intrauterine system in contraception.

Authors:  Tiina Backman
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

Review 8.  Controlled release for local delivery of drugs: barriers and models.

Authors:  Jennifer R Weiser; W Mark Saltzman
Journal:  J Control Release       Date:  2014-05-04       Impact factor: 9.776

Review 9.  Which Hormones and Contraception for Women with APS? Exogenous Hormone Use in Women with APS.

Authors:  Lisa R Sammaritano
Journal:  Curr Rheumatol Rep       Date:  2021-04-30       Impact factor: 4.592

Review 10.  Suppression of menstruation in adolescents with severe learning disabilities.

Authors:  Assunta Albanese; Neil W Hopper
Journal:  Arch Dis Child       Date:  2007-07       Impact factor: 3.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.